Recent evidence indicates that the c-Myc proto-oncogene activates transcription of cdc25A. The Cdc25A protein phosphatase is required both for progression through mitosis and for Myc-induced apoptosis, making cdc25A the most attractive Myc target gene identified so far.
The c-myc proto-oncogene has been extensively studied and its product is the best-characterized member of the Myc family of short-lived nuclear phosphoproteins (c-, N-, L-, S-and B-Myc; for a review of Myc proteins see [1] ). Expression of one or other myc genes is observed in virtually every human tumour, indicating that Myc function is very highly selected during carcinogenesis, and is perhaps mandatory. In normal cells, c-myc expression is tightly regulated in response to growth signals. Non-proliferating or quiescent cells generally express no detectable c-myc but the gene is rapidly induced following mitogenic stimulation and, thereafter, continues to be expressed (at very low levels) in proliferating cells. Induction of c-myc expression is both necessary and, at least in certain cell types, sufficient for progression through the first and subsequent cell cycles. Upon mitogen withdrawal, c-Myc protein is rapidly cleared from cells, a phenomenon that is facilitated by the very short half lives of both its mRNA and protein [2, 3] . Fibroblasts in which c-Myc is experimentally deregulated so that the cells can no longer downregulate c-Myc expression upon mitogen withdrawal become unable to leave the cell cycle.
Given the growth-promoting properties of c-myc, it may seem paradoxical that c-myc is also a potent inducer of apoptosis [4, 5] , a cell suicide programme that is, self-evidently, opposed to cell proliferation. Induction of apoptosis by c-Myc is promoted by growth-factor deprivation or by physical or genotoxic trauma [4] and is suppressed by specific cytokine survival factors or anti-apoptotic proteins such as Bcl-2 [6] [7] [8] . Two main models have been proposed to explain induction of apoptosis by c-Myc [9] : one posits that cell death results from a conflict between growth-promoting (Myc-mediated) and growth-arresting signals; the other presumes that both induction of mitogenesis and induction of apoptosis are normal functions of Myc, with other signals determining which eventually occurs. At present, however, the molecular basis for how c-Myc induces either apoptosis or cell proliferation remains unknown.
The c-Myc protein is a transcriptional modulator of the basic helix-loop-helix-leucine zipper (bHLH Zip) family. The bHLH Zip domain mediates sequence-specific DNA binding and dimerization with relevant partner proteins [10] ; it lies at the carboxyl terminus of c-Myc, together with two nuclear localization signals. The amino-terminal region of c-Myc contains a transcriptional activation domain. All of these structural features are required for all known functions of c-Myc -cell transformation, induction of cell proliferation, c-Myc autoregulation and induction of apoptosis. This strongly implies that c-Myc exerts its biological effects as a transcription factor, although other functions cannot be formally excluded.
The partner protein of c-Myc in vivo is another bHLH Zip protein, Max. Dimerization of Max with c-Myc is a prerequisite for all known c-Myc functions and is required for sequence-specific DNA binding by c-Myc. Max can also form homodimers and is the obligate dimerization partner of another family of bHLH Zip polypeptides, the Mad proteins. Indeed, Myc and Mad proteins compete for binding to Max which thus lies at the hub of a Myc-Max-Mad network. Max-Mad dimers antagonize the mitogenic actions of Myc-Max dimers and recruit various proteins that function as transcriptional co-repressors. Myc-Max heterodimers bind to a DNA consensus sequence, CACGTG, commonly referred to as the 'E box'. Interactions are also observed, however, between c-Myc and so-called 'noncanonical' E box-related binding sites, including the hexamers CATGTG, CATGCG, CACGCG, CACGAG, and one heptamer, CAACGTG [11] .
Because all evidence indicates that c-Myc acts as a transcription factor, there has long been great interest in identifying genes that are transcriptionally regulated by Myc -'target genes' -but very few have been identified. Candidates include the gene for ␣-prothymosin (function unknown) [12] ; ODC, the gene encoding ornithine decarboxylase [13] , a rate-limiting enzyme for polyamine biosynthesis that is essential for progression into S phase; ECA39, a developmentally regulated gene of unknown function that is overexpressed in some brain tumours [14] ; the tumour suppressor gene p53 [15] ; cad, which is required for de novo synthesis of pyrimidines; eIF-2␣, encoding the eukaryotic translational initiation factor 2␣ [16] ; and MrDb, which encodes an evolutionarily conserved RNA helicase of the DEAD-box family [11] . Some of these genes, such as ODC and cad, are clearly required in proliferating cells. None, however, can provide a satisfying mechanistic explanation for how c-Myc initiates and maintains cell proliferation or promotes apoptosis.
If c-Myc is such a potent inducer of cell proliferation, it must presumably interface in some way with the cell-cycle 'machinery'. Transition through the mammalian cell cycle is promoted by cyclin-dependent kinases (Cdks) and their regulatory subunits, the cyclins. During G1 phase of the cell cycle, cyclin D1-Cdk4 (or cyclin D1-cdk6) and cyclin E-Cdk2 complexes are active. Both cooperate to phosphorylate and inactivate the retinoblastoma protein, pRb, which, in its hypophosphorylated form, restrains progression from the G1 phase of the cell cycle into S phase (Fig.  1) . Induction of Myc in fibroblasts that have had their cell cycle arrested by growth to confluence triggers rapid hyperphosphorylation of pRb and activation of both cyclin D1-and cyclin E-associated kinase activities in the absence of significant changes in the absolute amounts of cyclin-Cdk complexes [17] . Myc-induced activation of the G1 cyclin complexes leads to up-regulation of cyclin A mRNA [18] , accompanied by transition through the cell cycle. Thus, the most likely mediators of a role for c-Myc in cell-cycle entry and progression are the G1 cyclin-Cdks and their regulators.
A new c-Myc target gene that has been identified in a recent paper by Galaktionov et al. [19] has many of the credentials of a mediator between c-Myc and the cellcycle regulatory mechanism. This gene, cdc25A, encodes a crucial G1-specific protein phosphatase that is required for the initiation of the cell cycle and for its progression through G1. Cdks are regulated positively and negatively by several independent mechanisms. Their activation requires both association with the appropriate cyclin and phosphorylation by a Cdk-activating kinase (CAK). Cdk activity is suppressed by interactions with Cdk-inhibitory proteins (p16, p21 and p27) and by phosphorylation at conserved threonine and tyrosine residues, usually at positions 14 and 15 of the Cdk. Dephosphorylation of these residues, with concomitant Cdk activation, is mediated by phosphatases of the Cdc25 family. Three human Cdk-activating phosphatases have been identified: Cdc25A, which is expressed early in G1 phase; Cdc25B, expressed during late-G1 phase close to the G1-S-phase transition; and Cdc25C, which is activated in G2 phase. Substantial evidence implicates Cdk2, and possibly Cdk4, as the physiological substrates of Cdc25A whose dephosphorylation allows progress through the cell cycle.
Galaktionov et al. [19] showed that cdc25A (and potentially also cdc25B) mRNA and protein product become abundant following ectopic activation of Myc in mouse and rat cell lines. This induction of cdc25A mRNA is not affected by the protein synthesis inhibitor cycloheximide, indicating that induction of cdc25A mRNA is a direct consequence of c-Myc action on the cdc25A gene and not dependent on some intermediary gene product induced by c-Myc. Consistent with this idea, sequence analysis revealed the presence of three potential Myc-Max binding sites in the human cdc25A gene. The first two have the non-canonical nucleotide sequence CATGTG and lie within the first intron, the third is a canonical CACGTG E box in the second intron. These three sites bind c-Myc directly in vitro and are sufficient to confer cMyc-dependence on the transcriptional activation of a heterologous promoter. Moreover, the locations of the E boxes in cdc25A resemble those of Myc sites in other Myc target genes (typically in introns distant from the start of transcription). By contrast, genes regulated by other bHLH Zip transcription factors that share specificity for the Myc E-box motif tend to have E boxes near the start site for transcription.
The evidence is, thus, very strong that cdc25A is a direct transcriptional target of c-Myc. Given the ability of Cdc25A to cause entry of mammalian cells into G1 phase, it is an excellent candidate for a mitogenic effector of cMyc. Indeed, cdc25A and c-myc gene expression patterns overlap in the mouse. During murine embryogenesis, c-myc important for further cell-cycle progression. Active Cdc25A phosphatase is also necessary for Myc-induced apoptosis [19] , whereas Cdk activity (at least in fibroblasts) seems not to be needed for induction of cell death [18] (although elevated cyclin D levels may be important in some forms of neuronal cell death).
and cdc25A are expressed in most developing embryonic organs, and in the adult mouse both are expressed in kidney, liver and heart, albeit at low levels. (As both c-Myc and cdc25A are essential for cell proliferation, however, coincident expression in proliferating cells is perhaps not surprising.)
Because c-Myc induces apoptosis as well as cell proliferation, might apoptosis also use cdc25A as an effector? Galaktionov and colleagues [19] demonstrated that Cdc25A induces apoptosis in serum-deprived fibroblasts, exactly as does c-Myc. Moreover, suppression of Cdc25A expression using antisense RNA substantially diminished the ability of c-Myc to promote apoptosis. Cdc25A appears, at the very least, necessary for c-Myc-induced apoptosis; quite possibly it is also a principal effector of the c-Myc death pathway. It therefore seems likely that the cell proliferation and cell death pathways bifurcate downstream of c-Myc and that both are channelled through Cdc25A.
If cdc25A is the principal effector of c-Myc, is it a protooncogene? Both cdc25A and cdc25B are, like c-myc, expressed at elevated levels in certain primary breast tumours. Indeed, this observation first prompted the investigation of cdc25A regulation by Myc. Many cellcycle regulators are expressed at elevated levels in tumours, however, and this overexpression may often reflect, rather than cause, the rapid proliferation of tumour cells. There is little evidence to indicate that deregulated expression of cdc25A is as ubiquitous as that of c-myc in tumours, which might imply that the two genes have subtly different functional attributes. Both cdc25A and cdc25B share with c-myc the ability to co-operate with Haras in the oncogenic transformation of cultured primary rodent fibroblasts [20] , however, so they can function as oncogenes in vitro.
Is cdc25A thus the complete solution to the long-standing mystery of Myc biology? Almost certainly not. Other Myc targets are known and there are almost certainly more: Myc probably serves to coordinate multiple genetic programmes during cell proliferation. Some of c-Myc's functions, including induction of apoptosis [21] , can occur throughout the cell cycle but it is unclear whether Cdc25A has any role later in the cell cycle than G1. There is also the problem of the kinetics of induction of cdc25A following c-Myc activation. The induction cdc25A mRNA was analyzed in mouse cells that express a ␤-oestradioldependent conditional allele of c-Myc. Although c-myc activation by steroid was very rapid in this system, the cdc25A mRNA level peaked only after about eight hours. It is not immediately obvious why it should take so long to induce a direct target of c-Myc. A similar time lag was observed between the appearance of Myc protein and maximum induction of cdc25A mRNA in quiescent NRK fibroblasts following mitogenic stimulation: c-Myc protein was expressed within the first couple of hours after addition of serum, but cdc25A mRNA expression peaked only after some 9 hours [22] .
Another difficulty that needs to be addressed is the finding by Steiner et al. [17] that activation of cyclin E-cdk2 in serum-deprived cells occurs in two steps. The first is triggered by Myc and involves the release of a 120 kDa cyclin E-cdk2 complex from a 250 kDa inactive precursor. This dissociation involves, at least in part, loss of the p27 Cdk inhibitor and is necessary, but not sufficient, to generate full cyclin E-cdk2 kinase activity. In such mitogen-deprived conditions, Cdc25 phosphatase activity is limiting and is not induced by Myc activity. Full activation of Cdc25A, required for cdk2 activation by dephosphorylation, is only achieved following mitogen stimulation. Thus, although c-Myc may induce Cdc25A expression, it is insufficient for full activation of the phosphatase.
Clearly, these discrepancies need to be explained. One straightforward approach to testing whether transcriptional up-regulation of cdc25A by Myc is a general mechanism for Myc's function in mitogenesis (and possibly apoptosis) is to determine if Myc-dependent regulation of cdc25A occurs in other cell types and across speciesin particular, whether the Myc/Max binding sites in the first and second introns of human cdc25A are evolutionarily conserved. Nonetheless, only the most pessimistic and cautious would argue that cdc25A is anything other than a terrific c-Myc transcriptional target. It is in the right place at about the right time, its 'face' fits and it is eminently qualified. Only time will tell whether it is really up to the job.
